A Multisite International Collaborative Phase 2 Study of Neoadjuvant Goserelin and a Non-steroidal Aromatase Inhibitor for Premenopausal Women With Estrogen Receptor Positive HER2 Negative Clinical Stage 2 and 3 Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2013
At a glance
- Drugs Anastrozole (Primary) ; Goserelin (Primary) ; Letrozole (Primary) ; Antineoplastics
- Indications Breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 19 Mar 2013 Planned end date changed from 1 Dec 2013 to 1 Sep 2021 as reported by ClinicalTrials.gov.
- 19 Mar 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.